---
title: "PharmaBlock Sciences (Nanjing), Inc. (300725.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300725.SZ.md"
symbol: "300725.SZ"
name: "PharmaBlock Sciences (Nanjing), Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T22:52:47.881Z"
locales:
  - [en](https://longbridge.com/en/quote/300725.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300725.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300725.SZ.md)
---

# PharmaBlock Sciences (Nanjing), Inc. (300725.SZ)

## Company Overview

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.pharmablock.com](https://www.pharmablock.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: B (0.34)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 30 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 14.80% |  |
| Net Profit YoY | -4.38% |  |
| P/B Ratio | 1.58 |  |
| Dividend Ratio | 0.64% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8696335121.10 |  |
| Revenue | 2025554714.88 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.62% | C |
| Profit Margin | 9.71% | B |
| Gross Margin | 32.14% | C |
| Revenue YoY | 14.80% | B |
| Net Profit YoY | -4.38% | C |
| Total Assets YoY | 30.01% | A |
| Net Assets YoY | 81.82% | A |
| Cash Flow Margin | 239.39% | A |
| OCF YoY | 14.80% | B |
| Turnover | 0.36 | C |
| Gearing Ratio | 13.95% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - PharmaBlock Sciences (Nanjing), Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "14.80%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.38%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.58",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.64%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8696335121.10",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2025554714.88",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.62%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "9.71%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "32.14%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "14.80%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.38%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "30.01%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "81.82%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "239.39%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "14.80%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.36",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.95%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 44.44 | 96/215 | 49.23 | 46.18 | 41.16 |
| PB | 1.59 | 50/215 | 2.74 | 1.65 | 1.26 |
| PS (TTM) | 4.31 | 113/215 | 5.10 | 4.65 | 4.38 |
| Dividend Yield | 0.64% | 119/215 | 0.66% | 0.61% | 0.58% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 37.41 |
| Highest Target | 47.00 |
| Lowest Target | 47.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300725.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300725.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300725.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300725.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**